Research review of 2017
12 December 2017
It has been an incredible year of research for the clinicians and researchers at Melanoma Institute Australia. It is through the sheer passion and commitment of the MIA team that productivity has continued to increase throughout 2017.
In the past year, there has been an impressive output of scientific publications with more than 120 produced, many of them in highly prestigious journals including Nature, New England Journal of Medicine and A Cancer Journal for Clinicians. In addition, we have presented our practice-changing research at several major conferences around the world, including the American Society of Clinical Oncology Annual Meeting in Chicago and the European Society for Medical Oncology Congress in Spain.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year:
- Ground-breaking work from our Australian Melanoma Genome Project was published in the renowned journal Nature. We identified the genetic changes in acral and mucosal melanoma that confirmed them as distinct diseases from cutaneous melanoma. [Read more]
- Our patient database underpinned the development of the latest American Joint Committee on Cancer staging for melanoma. [Read more]
- Results from two clinical trials of adjuvant systemic therapies made headlines across the globe. These findings will undoubtedly change the way we treat Stage III patients in future. [Read more]
- Findings from a large international clinical trial were detailed, which will change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost. Patients from MIA formed the largest cohort in this trial. [Read more]
- In the ABC clinical trial, developed and run by investigators at MIA, “game-changing” results demonstrated that combination immunotherapy can have increased life expectancy in advanced melanoma patients with brain metastases. [Read more]
- We published results from an international clinical trial of a new treatment that combines the antibody pembrolizumab with a cancer-killing virus (called TVEC) that was shown to improve outcomes for patients with advanced melanoma. [Read more]
- Nationally MIA, together with Cancer Council Australia, progressed the development of the new Melanoma Clinical Management Guidelines. [Read more]
The past few years have certainly been an exciting time for melanoma research and this year was no exception. The multidisciplinary team at MIA continues to strive towards our goal of zero deaths from melanoma. And with your ongoing support, we will get there!